The bone anabolic drug teriparatide, the first FDA-approved bone antimetabolic therapy, is a recombinant human parathyroid hormone amino-terminal 1–34 active fragment, which is biologically active in the same way as human parathyroid hormone, and increases lumbar vertebrae and femoral neck bone mineral density over the long term, and is an effective drug for reducing the risk of vertebral fracture in postmenopausal women with osteoporosis. The gene discussed is PTH; the disease is osteoporosis.